The role of oncolytic virus immunotherapies to subvert cancer immune evasion Journal Articles

abstract

• ABSTRACT  Despite huge economic and intellectual investments, developing effective cancer treatments continues to be an overarching challenge. Engineered oncolytic viruses (OVs) present self-amplifying immunotherapy platforms capable of preferential cytotoxicity to cancer cells and simultaneous activation of host anti-tumor immunity. In preclinical studies, OVs are showing potent therapeutic effects when used in combination with other immune therapy strategies. In the clinic, the immunotherapeutic effects of OVs are showing promising results. Here we review current strategies for engineering OVs, and present a perspective of future directions within a discussion of the current outcomes of combinatorial approaches with other cancer immunotherapy platforms.

authors

• Workenhe, Samuel Tekeste
• Verschoor, Meghan L
• Mossman, Karen

status

• published 

publication date

• February 2015

has subject area

• 1112 Oncology and Carcinogenesis (FoR)
• Animals (MeSH)
• Combined Modality Therapy (MeSH)
• Humans (MeSH)
• Immune Tolerance (MeSH)
• Immunologic Surveillance (MeSH)
• Immunotherapy (MeSH)
• Neoplasms (MeSH)
• Oncology & Carcinogenesis (Science Metrix)
• Oncolytic Virotherapy (MeSH)
• Oncolytic Viruses (MeSH)
• Tumor Escape (MeSH)
• Virus Replication (MeSH)

published in

• Future Oncology  Journal

keywords

• Animals
• Combined Modality Therapy
• Humans
• Immune Tolerance
• Immunologic Surveillance
• Immunotherapy
• Neoplasms
• Oncolytic Virotherapy
• Oncolytic Viruses
• Tumor Escape
• Virus Replication
• cancer immunotherapy
• oncolytic virus

Digital Object Identifier (DOI)

• 10.2217/fon.14.254

PubMed ID

• 25686121

start page

• 675

end page

• 689

volume

• 11

issue

• 4